Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) Leverages Genetics to Produce Potent CBD Strains Amid New Research Suggesting CBD Aids COVID-19 Patients

February 17, 2021 14:11:16
  • Austrian researchers report CBD reduces inflammation and speeds recovery in ICU COVID-19 patients
  • Research suggests CBD’s anti-inflammatory properties stave off long-term neurological damage associated with COVID-19
  • PACR leverages genetic technology to produce potent CBD strains with higher yields per growing season
  • Company catalog includes 350 cultivars and 50 super-elite strains prized in industry

CBD may soon become the newest support in the world’s fight against COVID-19: Researchers at the Klagenfurt Clinic in Austria recently reported positive results from cannabidiol (“CBD”) trials on COVID-19 patients that demonstrated reduced inflammation and quicker recovery times ( Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF), a Canada-based cannabis company dedicated to producing premium-quality strains and products through a genetics-focused approach, leverages genetic technology to cultivate unique strains prized in the industry for their potency and overall effectiveness.

CBD continues to gain mainstream attention among healthcare professionals and the general public as a way to address symptoms of chronic diseases – particularly those associated with…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.